IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Genovese, Mark C. [1 ]
Ogata, Atsushi [2 ,3 ]
Nomura, Akira [4 ]
Bao, Min [5 ]
Hitraya, Elena [6 ]
Lacey, Stuart [7 ]
Burmester, Gerd R. [8 ,9 ]
机构：
[1] Stanford Univ, Immunol & Rheumatol, Palo Alto, CA 94304 USA
[2] Osaka Univ, Grad Sch Med, Resp Med Allergy & Rheumat Dis, Osaka, Japan
[3] NTT West Osaka Hosp, Osaka, Japan
[4] Chugai Pharmaceut, Rheumatol, Tokyo, Japan
[5] Genentech Inc, Rheumatol, San Francisco, CA 94080 USA
[6] Crescendo Biosci, San Francisco, CA USA
[7] Roche Prod, Stat, Welwyn Garden City, Herts, England
[8] Free Univ Berlin, Rheumatol & Clin Immunol, Berlin, Germany
[9] Humboldt Univ, D-10099 Berlin, Germany
来源：
RHEUMATOLOGY | 2016年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
077
引用
收藏
页码：92 / 93
页数：2
相关论文
共 50 条
  • [1] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [2] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [3] The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
    Daniel H. Solomon
    Chang Xu
    Jamie Collins
    Seoyoung C. Kim
    Elena Losina
    Vincent Yau
    Fredrik D. Johansson
    [J]. Arthritis Research & Therapy, 23
  • [4] The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
    Solomon, Daniel H.
    Xu, Chang
    Collins, Jamie
    Kim, Seoyoung C.
    Losina, Elena
    Yau, Vincent
    Johansson, Fredrik D.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [5] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [6] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [7] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
  • [8] Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis
    Garrood, T
    Scott, DL
    [J]. BIODRUGS, 2001, 15 (08) : 543 - 561
  • [9] Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
    Toby Garrood
    David L. Scott
    [J]. BioDrugs, 2001, 15 : 543 - 561
  • [10] COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO PREVIOUS TREATMENTS
    Tymms, K.
    Littlejohn, G.
    Bossingham, D.
    Griffiths, H.
    Bagga, H.
    Clemens, L.
    Smith, M.
    Bird, P.
    Mpofu, C.
    Bernasconi, C.
    Bykerk, V.
    [J]. INTERNAL MEDICINE JOURNAL, 2012, 42 : 13 - 14
12345